Ahmed Kamran A, Wilder Richard B
Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Int Braz J Urol. 2015 Jan-Feb;41(1):78-85. doi: 10.1590/S1677-5538.IBJU.2015.01.11.
To evaluate post-orchiectomy utilization of radiation therapy (RT) versus other management approaches in stage IIA and IIB testicular seminoma patients.
Two hundred and forty-one patients with stage IIA and IIB testicular seminoma were identified between 1988 and 2003 using the Surveillance, Epidemiology, and End Results (SEER) database.
Median follow-up was 10 years. Patients with stage IIA disease underwent RT more frequently than those with stage IIB disease (72 % vs. 46 %, respectively; P < 0.001). There was no significant change in RT utilization for stage IIA or IIB disease between 1988 and 2003 (P = 0.89).
Between 1988 and 2003, stage IIA patients underwent RT more often than stage IIB patients in the United States. There was no significant change in RT utilization for stage IIA or IIB disease during this time period. Based on reports describing excellent progression-free survival with cisplatin-based chemotherapy, this approach has increased in popularity since 2003 and may eventually become the most popular treatment approach for both stage IIA and IIB testicular seminoma.
评估IIA期和IIB期睾丸精原细胞瘤患者睾丸切除术后放射治疗(RT)与其他治疗方法的应用情况。
利用监测、流行病学和最终结果(SEER)数据库,确定了1988年至2003年间的241例IIA期和IIB期睾丸精原细胞瘤患者。
中位随访时间为10年。IIA期疾病患者接受RT的频率高于IIB期疾病患者(分别为72%和46%;P<0.001)。1988年至2003年间,IIA期或IIB期疾病的RT应用情况无显著变化(P=0.89)。
1988年至2003年间,美国IIA期患者接受RT的频率高于IIB期患者。在此期间,IIA期或IIB期疾病的RT应用情况无显著变化。基于描述以顺铂为基础的化疗具有出色无进展生存期的报告,自2003年以来,这种方法越来越受欢迎,最终可能成为IIA期和IIB期睾丸精原细胞瘤最常用的治疗方法。